Ke, E., & Wu, Y. (2016). Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: A review of the clinical evidence. Ther Adv Respir Dis.
Chicago Stili AlıntıKe, E-E, ve Yi-Long Wu. "Afatinib in the First-line Treatment of Epidermal-growth-factor-receptor Mutation-positive Non-small Cell Lung Cancer: A Review of the Clinical Evidence." Ther Adv Respir Dis 2016.
MLA AlıntıKe, E-E, ve Yi-Long Wu. "Afatinib in the First-line Treatment of Epidermal-growth-factor-receptor Mutation-positive Non-small Cell Lung Cancer: A Review of the Clinical Evidence." Ther Adv Respir Dis 2016.
Uyarı: Bu alıntı herzaman %100 doğru olmayabilir..